In Vitro Activities of a New Des-fluoro(6) Quinolone, Garenoxacin, Against Clinical Anaerobic Bacteria

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2003 Oct 25

PMID 14576144

Citations 13

Authors

A Liebetrau

A C Rodloff

J Behra-Miellet

L Dubreuil

Affiliations

Soon will be listed here.

Abstract

The antimicrobial activities of garenoxacin and eight other antibiotics against 641 anaerobic isolates were evaluated with the NCCLS agar dilution method. Overall, the MICs of garenoxacin for 50 and 90% of the strains tested (in micrograms per milliliter) were as follows: Bacteroides fragilis group, 0.5 and 2; Prevotella spp., 0.25 and 2; Fusobacterium spp., 0.25 and 0.5; Porphyromonas spp., 0.125 and 0.25; Bilophila wadsworthia, 0.5 and 1; Veillonella spp., 0.25 and 0.5; Clostridium spp., 0.25 and 1; Clostridium difficile, 2 and >64; Bifidobacterium spp., 1 and 2; Eggerthella lenta, 0.25 and 1; Propionibacterium spp., 0.5 and 0.5; gram-positive cocci, 0.125 and 0.25.

Citing Articles

Fixed Drug Eruption Caused by Garenoxacin: A Case Report and Literature Review.

Hara N, Saito-Sasaki N, Sawada Y Cureus. 2023; 15(11):e48596.

PMID: 38084197 PMC: 10710661. DOI: 10.7759/cureus.48596.

Uptake of Ozenoxacin and Other Quinolones in Gram-Positive Bacteria.

Lopez Y, Munoz L, Gargallo-Viola D, Canton R, Vila J, Zsolt I Int J Mol Sci. 2021; 22(24).

PMID: 34948159 PMC: 8708121. DOI: 10.3390/ijms222413363.

Bacteremia in a Middle-Aged Healthy Man with Acute Hepatic Abscess: Case Report and Literature Review, 1970-2020.

Wang J, Guo R, Ma W, Dong X, Yan S, Xie W Infect Drug Resist. 2021; 14:3307-3318.

PMID: 34434054 PMC: 8382309. DOI: 10.2147/IDR.S321282.

Clinical and microbiological characteristics of Eggerthella lenta bacteremia.

Gardiner B, Tai A, Kotsanas D, Francis M, Roberts S, Ballard S J Clin Microbiol. 2014; 53(2):626-35.

PMID: 25520446 PMC: 4298500. DOI: 10.1128/JCM.02926-14.

Efficacy of rifaximin vaginal tablets in treatment of bacterial vaginosis: a molecular characterization of the vaginal microbiota.

Cruciani F, Brigidi P, Calanni F, Lauro V, Tacchi R, Donders G Antimicrob Agents Chemother. 2012; 56(8):4062-70.

PMID: 22585228 PMC: 3421556. DOI: 10.1128/AAC.00061-12.

References

Lubbe M, Botha P, Chalkley L . Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa. Eur J Clin Microbiol Infect Dis. 1999; 18(1):46-54. DOI: 10.1007/s100960050225. View

Wexler H, Molitoris E, Molitoris D, Finegold S . In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria. Antimicrob Agents Chemother. 1996; 40(9):2232-5. PMC: 163509. DOI: 10.1128/AAC.40.9.2232. View

Aldridge K, Ashcraft D, Cambre K, Pierson C, Jenkins S, Rosenblatt J . Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species. Antimicrob Agents Chemother. 2001; 45(4):1238-43. PMC: 90449. DOI: 10.1128/AAC.45.4.1238-1243.2001. View

Snydman D, Jacobus N, McDermott L, Supran S, Cuchural Jr G, Finegold S . Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother. 1999; 43(10):2417-22. PMC: 89494. DOI: 10.1128/AAC.43.10.2417. View

Dubreuil L, Breuil J, Dublanchet A, SEDALLIAN A . Survey of the susceptibility patterns of Bacteroides fragilis group strains in France from 1977 to 1992. Eur J Clin Microbiol Infect Dis. 1992; 11(11):1094-9. DOI: 10.1007/BF01967804. View

Grollier G, Mory F, Quentin C, Girard-Pipau F, Tigaud S, SEDALLIAN A . [Susceptibility of strict anaerobic bacteria to antibiotics in France: a multicenter study]. Pathol Biol (Paris). 1994; 42(5):498-504. View

Bassetti M, Dembry L, Farrel P, Callan D, Andriole V . Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates. Antimicrob Agents Chemother. 2001; 46(1):234-8. PMC: 126992. DOI: 10.1128/AAC.46.1.234-238.2002. View

Fix A, Pfaller M, Biedenbach D, Beach M, Jones R . Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Int J Antimicrob Agents. 2001; 18(2):141-5. DOI: 10.1016/s0924-8579(01)00361-2. View

Schaumann R, Ackermann G, Pless B, Claros M, Rodloff A . In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria. Antimicrob Agents Chemother. 1999; 43(11):2783-6. PMC: 89560. DOI: 10.1128/AAC.43.11.2783. View

10.

Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y . In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother. 1999; 43(5):1077-84. PMC: 89114. DOI: 10.1128/AAC.43.5.1077. View

11.

Goldstein E, Citron D . Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria. Antimicrob Agents Chemother. 1992; 36(5):1158-62. PMC: 188857. DOI: 10.1128/AAC.36.5.1158. View

12.

Ackermann G, Schaumann R, Pless B, Claros M, Goldstein E, Rodloff A . Comparative activity of moxifloxacin in vitro against obligately anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 2000; 19(3):228-32. DOI: 10.1007/s100960050465. View

13.

Betriu C, Gomez M, Palau M, Sanchez A, Picazo J . Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group: comparison with the activities of 14 other agents. Antimicrob Agents Chemother. 1999; 43(9):2320-2. PMC: 89472. DOI: 10.1128/AAC.43.9.2320. View

14.

Bauernfeind A . Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1998; 40(5):639-51. DOI: 10.1093/jac/40.5.639. View

15.

Ackermann G, Tang Y, Kueper R, Heisig P, Rodloff A, Silva Jr J . Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA. Antimicrob Agents Chemother. 2001; 45(8):2348-53. PMC: 90652. DOI: 10.1128/AAC.45.8.2348-2353.2001. View

16.

Soussy C, Carret G, Cavallo J, Chardon H, Chidiac C, Choutet P . [Antibiogram Committee of the French Microbiology Society. Report 2000-2001]. Pathol Biol (Paris). 2001; 48(9):832-71. View

17.

Weller T, Andrews J, Jevons G, Wise R . The in vitro activity of BMS-284756, a new des-fluorinated quinolone. J Antimicrob Chemother. 2001; 49(1):177-84. DOI: 10.1093/jac/49.1.177. View

18.

Spangler S, Jacobs M, Appelbaum P . Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes. Antimicrob Agents Chemother. 1994; 38(10):2471-6. PMC: 284766. DOI: 10.1128/AAC.38.10.2471. View

19.

Patey O, Varon E, Prazuck T, Podglajen I, Dublanchet A, Dubreuil L . Multicentre survey in France of the antimicrobial susceptibilities of 416 blood culture isolates of the Bacteroides fragilis group. J Antimicrob Chemother. 1994; 33(5):1029-34. DOI: 10.1093/jac/33.5.1029. View

20.

Bauernfeind A . Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. J Antimicrob Chemother. 1993; 31(4):505-22. DOI: 10.1093/jac/31.4.505. View